This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nuvo Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Jesse Ledger

Algemeen directeur

CA$753.5k

Totale compensatie

Percentage CEO-salaris	49.7%
Dienstverband CEO	6.3yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	6.3yrs
Gemiddelde ambtstermijn bestuur	17.5yrs

Recente managementupdates

Nuvo Pharmaceuticals Inc.'s (TSE:MRV) CEO Might Not Expect Shareholders To Be So Generous This Year

May 11

Recent updates

Nuvo Pharmaceuticals (TSE:MRV) Has A Somewhat Strained Balance Sheet

Aug 17

Is Nuvo Pharmaceuticals (TSE:MRV) Using Too Much Debt?

Sep 01

Nuvo Pharmaceuticals Inc.'s (TSE:MRV) CEO Might Not Expect Shareholders To Be So Generous This Year

May 11

These 4 Measures Indicate That Nuvo Pharmaceuticals (TSE:MRV) Is Using Debt Extensively

Feb 22

Analyse CEO-vergoeding

Hoe is Jesse Ledger's beloning veranderd ten opzichte van Nuvo Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2022	n/a	n/a	CA$15m
Jun 30 2022	n/a	n/a	-CA$3m
Mar 31 2022	n/a	n/a	-CA$12m
Dec 31 2021	CA$754k	CA$375k	-CA$32m
Sep 30 2021	n/a	n/a	-CA$24m
Jun 30 2021	n/a	n/a	-CA$9m
Mar 31 2021	n/a	n/a	-CA$20m
Dec 31 2020	CA$577k	CA$369k	-CA$4m
Sep 30 2020	n/a	n/a	-CA$7m
Jun 30 2020	n/a	n/a	CA$311k
Mar 31 2020	n/a	n/a	CA$9m
Dec 31 2019	CA$715k	CA$350k	CA$3m
Sep 30 2019	n/a	n/a	-CA$814k
Jun 30 2019	n/a	n/a	-CA$8m
Mar 31 2019	n/a	n/a	-CA$13m
Dec 31 2018	CA$546k	CA$350k	-CA$6m
Sep 30 2018	n/a	n/a	-CA$2m
Jun 30 2018	n/a	n/a	CA$473k
Mar 31 2018	n/a	n/a	-CA$784k
Dec 31 2017	CA$621k	CA$292k	CA$2m
Sep 30 2017	n/a	n/a	CA$4m
Jun 30 2017	n/a	n/a	CA$5m
Mar 31 2017	n/a	n/a	CA$8m
Dec 31 2016	CA$300k	CA$170k	CA$7m

Compensatie versus markt: De totale vergoeding ($USD 549.24K ) Jesse } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 170.34K ).

Compensatie versus inkomsten: De vergoeding van Jesse is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jesse Ledger

6.3yrs

Tenure

CA$753,546

Compensatie

Mr. Jesse F. Ledger has been the Chief Executive Officer of Nuvo Pharmaceuticals Inc. since November 21, 2017 and as its President since November 15, 2016. Mr. Ledger served as Vice President of Business D...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jesse Ledger	President & CEO	6.3yrs	CA$753.55k	1.09% CA$ 167.1k
Mary-Jane Burkett	VP & CFO	6.5yrs	CA$394.05k	0.14% CA$ 21.8k
Bernard Chiasson	VP of Operations & Chief Scientific Officer	5.5yrs	CA$508.45k	0.098% CA$ 15.0k
Katina Loucaides	VP, Corporate Secretary & General Counsel	no data	CA$509.20k	0.20% CA$ 31.2k
Luigi Berardelli	Vice President of Sales & Marketing	no data	CA$448.72k	geen gegevens

6.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van MRV is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anthony Dobranowski	Independent Lead Director	18.5yrs	CA$66.75k	0.61% CA$ 94.5k
Rolf Zinkernagel	Member of Scientific Advisory Board	17.5yrs	geen gegevens	geen gegevens
Stefan Meuer	Member of Scientific Advisory Board	17.5yrs	geen gegevens	geen gegevens
Lee Simon	Member of Scientific Advisory Board	17.5yrs	geen gegevens	geen gegevens
John London	Non-Executive Vice-Chairman	18.5yrs	CA$58.75k	1.37% CA$ 210.3k
Daniel Chicoine	Independent Director	18.5yrs	CA$60.75k	2.07% CA$ 318.3k
Mary Ritchie	Independent Director	1.8yrs	CA$36.86k	geen gegevens
Jonathan Wilkin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dale Weil	Independent Director	less than a year	geen gegevens	geen gegevens
Robert Harris	Non-Executive Chairman	5.8yrs	CA$93.33k	0.66% CA$ 101.2k
Anthony Snow	Director	less than a year	geen gegevens	geen gegevens

17.5yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MRV zijn ervaren en ervaren (gemiddelde ambtstermijn van 17.5 jaar).

This company listing is no longer active

Nuvo Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors

Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors

Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to Its Board of Directors

Nuvo Pharmaceuticals Inc., Annual General Meeting, May 16, 2022

Nuvo Pharmaceuticals Inc.'s (TSE:MRV) CEO Might Not Expect Shareholders To Be So Generous This Year

Nuvo Pharmaceuticals Inc., Annual General Meeting, May 17, 2021

Recent updates

Price target decreased to CA$1.20

Nuvo Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 14, 2022

Nuvo Pharmaceuticals (TSE:MRV) Has A Somewhat Strained Balance Sheet

Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors

Second quarter 2022 earnings released: EPS: CA$1.61 (vs CA$0.80 in 2Q 2021)

Nuvo Pharmaceuticals Inc. Appoints Anthony Snow to the Board of Directors

Nuvo Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 15, 2022

Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to Its Board of Directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Nuvo Pharmaceuticals Inc. Provides an Update on the United States Pennsaid® 2% Business

Nuvo Pharmaceuticals Inc. to Report Q1, 2022 Results on May 16, 2022

Price target increased to CA$2.60

Full year 2021 earnings: EPS exceeds analyst expectations

Nuvo Pharmaceuticals Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2021

Nuvo Pharmaceuticals Inc., Annual General Meeting, May 16, 2022

Nuvo Pharmaceuticals Inc. Announces Summary Judgment Ruling by the United States District Court for the District of New Jersey

Third quarter 2021 earnings released: CA$1.56 loss per share (vs CA$0.25 loss in 3Q 2020)

Is Nuvo Pharmaceuticals (TSE:MRV) Using Too Much Debt?

Second quarter 2021 earnings released: EPS CA$0.80 (vs CA$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: CA$1.58 loss per share (vs CA$0.15 loss in 1Q 2020)

Nuvo Pharmaceuticals Inc.'s (TSE:MRV) CEO Might Not Expect Shareholders To Be So Generous This Year

Full year 2020 earnings released: CA$0.36 loss per share (vs CA$0.30 profit in FY 2019)

Revenue and earnings beat expectations

Miravo Healthcaretm Ireland Enters into Resultz® License and Supply Agreement with the Mentholatum Company for the United States

Nuvo Pharmaceuticals Inc., Annual General Meeting, May 17, 2021

Nuvo Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 08, 2021

These 4 Measures Indicate That Nuvo Pharmaceuticals (TSE:MRV) Is Using Debt Extensively

Miravo Healthcare Announces the Canadian Commercial Launch of NeoVisc®+ and NeoVisc® ONE for the Treatment of Pain and Improvement of Joint Functionality of the Knee

New 90-day high: CA$1.06

Third quarter 2020 earnings released: CA$0.25 loss per share

Revenue beats expectations, earnings disappoint

Nuvo Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 16, 2020

New 90-day high: CA$0.93

Nuvo Pharmaceuticals Inc. (TSX:NRI) completed the acquisition of Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc. (TSX:ARZ).

New 90-day high: CA$0.80

Nuvo Pharmaceuticals Inc. to Report Q2, 2020 Results on Aug 10, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd